Massey Ventures has a portfolio of licensing deals with our industry partners. Check out some of our case studies below.
Strawberry birthmarks are disfiguring, and potentially life-threatening tumours affecting 1-in-10 children worldwide. Current treatments are reserved for only the most severe cases, due to drug related side-effects. In 2022, Massey Ventures and the Gillies McIndoe Research Institute (GMRI) announced an agreement with AFT Pharmaceuticals to develop a life-changing new treatment for infants' and their families in over 100 countries.
In Pakistan, where one in two children are iron deficient, global food giant Nestlé announced the launch of BUNYAD IRON+, an affordable dairy-based drink fortified with a new source of iron in 2022. The unique iron source has three times greater absorption than alternative sources. The FERRI-PRO technology, originally developed by the Riddet Institute at Massey University, was acquired by Nestlé in December 2018. The deal remains the biggest in the University's history, both in terms of commercial and societal impact.
Massey Ventures has a portfolio of spinouts and investments. Check out our current portfolio below.
Retrabac Therapeutics Ltd is developing a topical anti-bacterial treatment combining three known compounds to target resistant bacteria.
Initial applications will focus on treating burns and soft tissue infection.
A co-investment with the Matū Fund, Ampersand Technologies Ltd is developing fast, cheap and accurate DNA-based diagnostics for horticulture, agriculture and environmental applications.
The first diagnostic test proved effective in identifying the pathogen responsible for kāuri dieback, a disease threatening New Zealand’s native kāuri tree.
HARDL is an R&D company utilizing hyperspectral imaging technology for a range of applications. It is the shareholder in Hyperceptions Ltd
A joint venture between NZ company Comfort Group and Massey Ventures. Compress Tech Ltd will commercialize a pressure sensing surface with multiple applications.
Comfort Group has an exclusive license to use the technology in beds.